201 related articles for article (PubMed ID: 26655846)
1. A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors.
Goff LW; Cohen RB; Berlin JD; de Braud FG; Lyshchik A; Noberasco C; Bertolini F; Carpentieri M; Stampino CG; Abbattista A; Wang E; Borghaei H
Clin Cancer Res; 2016 May; 22(9):2146-54. PubMed ID: 26655846
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors.
Doi T; Lee KH; Kim TM; Ohtsu A; Kim TY; Ikeda M; Yoh K; Gallo Stampino C; Hirohashi T; Suzuki A; Fujii Y; Andrew Williams J; Bang YJ
Cancer Med; 2016 Jul; 5(7):1454-63. PubMed ID: 27075560
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.
Simonelli M; Zucali P; Santoro A; Thomas MB; de Braud FG; Borghaei H; Berlin J; Denlinger CS; Noberasco C; Rimassa L; Kim TY; English PA; Abbattista A; Gallo Stampino C; Carpentieri M; Williams JA
Ann Oncol; 2016 Sep; 27(9):1782-7. PubMed ID: 27329247
[TBL] [Abstract][Full Text] [Related]
4. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
Chiorean EG; LoRusso P; Strother RM; Diamond JR; Younger A; Messersmith WA; Adriaens L; Liu L; Kao RJ; DiCioccio AT; Kostic A; Leek R; Harris A; Jimeno A
Clin Cancer Res; 2015 Jun; 21(12):2695-703. PubMed ID: 25724527
[TBL] [Abstract][Full Text] [Related]
5. First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors.
Garrido-Laguna I; Krop I; Burris HA; Hamilton E; Braiteh F; Weise AM; Abu-Khalaf M; Werner TL; Pirie-Shepherd S; Zopf CJ; Lakshminarayanan M; Holland JS; Baffa R; Hong DS
Int J Cancer; 2019 Oct; 145(7):1798-1808. PubMed ID: 30680712
[TBL] [Abstract][Full Text] [Related]
6. A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.
Papadopoulos KP; Kelley RK; Tolcher AW; Razak AR; Van Loon K; Patnaik A; Bedard PL; Alfaro AA; Beeram M; Adriaens L; Brownstein CM; Lowy I; Kostic A; Trail PA; Gao B; DiCioccio AT; Siu LL
Clin Cancer Res; 2016 Mar; 22(6):1348-55. PubMed ID: 26490310
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
[TBL] [Abstract][Full Text] [Related]
8. A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors.
Diaz LA; Coughlin CM; Weil SC; Fishel J; Gounder MM; Lawrence S; Azad N; O'Shannessy DJ; Grasso L; Wustner J; Ebel W; Carvajal RD
Clin Cancer Res; 2015 Mar; 21(6):1281-8. PubMed ID: 25398449
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors.
Wagner AJ; Messersmith WA; Shaik MN; Li S; Zheng X; McLachlan KR; Cesari R; Courtney R; Levin WJ; El-Khoueiry AB
Clin Cancer Res; 2015 Mar; 21(5):1044-51. PubMed ID: 25388167
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.
Johnson ML; Braiteh F; Grilley-Olson JE; Chou J; Davda J; Forgie A; Li R; Jacobs I; Kazazi F; Hu-Lieskovan S
JAMA Oncol; 2019 Jul; 5(7):999-1007. PubMed ID: 31145415
[TBL] [Abstract][Full Text] [Related]
11. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
12. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.
Segal NH; He AR; Doi T; Levy R; Bhatia S; Pishvaian MJ; Cesari R; Chen Y; Davis CB; Huang B; Thall AD; Gopal AK
Clin Cancer Res; 2018 Apr; 24(8):1816-1823. PubMed ID: 29549159
[No Abstract] [Full Text] [Related]
13. A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors.
Rosen LS; Wesolowski R; Baffa R; Liao KH; Hua SY; Gibson BL; Pirie-Shepherd S; Tolcher AW
Invest New Drugs; 2020 Feb; 38(1):120-130. PubMed ID: 30887250
[TBL] [Abstract][Full Text] [Related]
14. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.
Hidalgo M; Martinez-Garcia M; Le Tourneau C; Massard C; Garralda E; Boni V; Taus A; Albanell J; Sablin MP; Alt M; Bahleda R; Varga A; Boetsch C; Franjkovic I; Heil F; Lahr A; Lechner K; Morel A; Nayak T; Rossomanno S; Smart K; Stubenrauch K; Krieter O
Clin Cancer Res; 2018 Apr; 24(7):1536-1545. PubMed ID: 29217526
[No Abstract] [Full Text] [Related]
15. A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).
Clarke JM; Blobe GC; Strickler JH; Uronis HE; Zafar SY; Morse M; Dropkin E; Howard L; O'Neill M; Rushing CN; Niedzwiecki D; Watson H; Bolch E; Arrowood C; Liu Y; Nixon AB; Hurwitz HI
Cancer Chemother Pharmacol; 2019 Oct; 84(4):909-917. PubMed ID: 31444620
[TBL] [Abstract][Full Text] [Related]
16. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.
Shapiro GI; Vaishampayan UN; LoRusso P; Barton J; Hua S; Reich SD; Shazer R; Taylor CT; Xuan D; Borghaei H
Invest New Drugs; 2017 Jun; 35(3):315-323. PubMed ID: 28070718
[TBL] [Abstract][Full Text] [Related]
17. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
[TBL] [Abstract][Full Text] [Related]
19. First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.
Shapiro GI; Bell-McGuinn KM; Molina JR; Bendell J; Spicer J; Kwak EL; Pandya SS; Millham R; Borzillo G; Pierce KJ; Han L; Houk BE; Gallo JD; Alsina M; Braña I; Tabernero J
Clin Cancer Res; 2015 Apr; 21(8):1888-95. PubMed ID: 25652454
[TBL] [Abstract][Full Text] [Related]
20. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.
King GT; Eaton KD; Beagle BR; Zopf CJ; Wong GY; Krupka HI; Hua SY; Messersmith WA; El-Khoueiry AB
Invest New Drugs; 2018 Oct; 36(5):836-847. PubMed ID: 29333575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]